With the recent release of the movie “Vaxxed: From Cover-Up to Catastrophe,” I’m seeing a few blog posts and articles pop up about the hegemonic Read More
African Business Magazine: Partnerships to fight disease “…Investing in the discovery, development, and manufacture of drugs to combat tropical and poverty-related diseases in African countries with limited resources to fund research or pay for treatments was a commercial non-starter. … The product development partnership (PDP) model, which emerged in the late 90s, was a response…More
by Jill B. Brelsford, Jordan L.
The recent devastating outbreak of Ebola virus disease led to the accelerated development of multiple candidate vaccines against this virus, with at least eight entering clinical trials in 2014–16.1 Direct evidence of 100% effectiveness against disease has been demonstrated for VSV-EBOV, a vaccine based on a replicating vesicular stomatitis virus genetically modified to express Ebola virus glycoprotein.2 This vaccine has been granted Breakthrough Therapy Designation status by the US Food and Drug Administration and PRIME status by the European Medicines Agency, and its single-dose regimen and proof of effectiveness from 10 days post-immunisation make it an attractive candidate for use in a responsive campaign (whether it be through ring immunisation around identified cases or as a whole-population intervention).
Typhoid, one of the classic infectious diseases afflicting humanity, is still a relatively common illness in many lower-income and middle-income countries (LMIC).1 The disease is associated with chronic fever that, if not treated, can lead to complications such as intestinal perforation or neurological problems.2 The diagnosis of typhoid is complicated because clinical presentation can be non-specific and can resemble a number of other diseases, such as malaria, typhus, and various viral infections.
Bill & Melinda Gates Foundation’s “Impatient Optimists”: Innovation: Everything Old is New Again Trevor Mundel, president of global health at the Bill & Melinda Gates Foundation, discusses the work of Miguel Prudencio and his colleagues at Lisbon’s Instituto de Medicina Molecular, who are attempting to use an older approach to vaccine development and apply it…More
by Stephen Nash, Alexander J. Mentzer, Swaib A. Lule, Dennison Kizito, Gaby Smits, Fiona R.
Economic Times: Gates foundation interested in preventing infectious diseases: Keith Klugman, Bill & Melinda Gates Foundation “India is expected to roll out Pfizer’s 13-valent pneumococcal conjugate vaccine (PCV), Prevnar13, as part of its universal immunization program this year. The vaccine, procured from the Global Alliance for Vaccines and Immunization (Gavi) at $3.2-3.3 (Rs218-225) per dose,…More
Scientific American: Rapid-Response Vaccines for Epidemic Outbreaks In this podcast, “Trevor Mundel, president of global health at the Gates Foundation, talks to Scientific American Editor-in-Chief Mariette DiChristina about the Coalition for Epidemic Preparedness Innovations (CEPI) and the efforts to create vaccine platforms for rapid responses to epidemics…” (DiChristina/Mirsky, 1/30).
Nature: Vaccine initiative marks bold resolution Editorial Board “…For too long, the world has fatalistically acquiesced to a status quo in which, because there is no market for vaccines against pathogens that might never cause a major problem, there is no substantial investment in developing vaccines against them. Clearly, private companies cannot be expected to…More
PLOS NTDs co-Editor-in-Chief Peter Hotez lists the key scientific papers refuting the myth that vaccines cause autism I have a unique perspective on the recent headlines surrounding vaccines and their alleged links to autism. I
STAT: We’re not prepared for future Ebola outbreaks, experts warn “Despite recent headlines declaring the success of an experimental Ebola vaccine, the world is not fully prepared for future epidemics — and not in position to use vaccines to prevent another deadly outbreak, a report published Tuesday warned. The report raised serious concerns about the…More
U.N. News Centre: U.N. agency hails new polio vaccination regimen in South-East Asia that curbs impact on global supply “Amid a global shortage of injectable inactivated polio vaccines (IPV), a new inoculation regimen, employed by governments in the South-East Asian region, involving two fractional vaccine doses — each about a fifth of a full dose…More
CNBC: Prepping vaccines is only one way to prepare for the next epidemic “…[T]hough responses [to disease outbreaks] have accelerated, public health defenses don’t galvanize until after the threat has emerged. To get ahead of the next epidemic, a new group has been formed, called CEPI, which stands for Coalition for Epidemic Preparedness Innovations. Its…More
New York Times: A Zika Vaccine, but for Whom? Patrick Adams, freelance journalist, and Cameron Nutt, student at Harvard Medical School “The race for a Zika vaccine, one of the most pressing priorities in global health, is at full throttle. More than a dozen companies and government institutions are working to unlock the secrets of…More